Evaluation of Pretransplant Donor-Specific Alloantibodies With Different Crossmatch Techniques

Moszkowska, Grażyna; Zieliński, Maciej; Zielińska, Hanna; Dukat-Mazurek, Anna; Dębska-Zielkowska, Joanna; Dębska-Ślizień, Alicja; Rutkowski, Bolesław; Trzonkowski, Piotr

doi:10.1016/j.transproceed.2018.02.165

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another standard testing before transplantation is detection of recipient alloantibodies and their specificity. Matching them with donor HLA databases (virtual PRA (vPRA)) or donor HLA antigens (virtual crossmatch (V-XM)) better predicts patients' transplantability [ 82 , 83 ]. Novel concept of HLA matching is based on specific immunogenic epitopes of HLA antigens termed eplets.…”

Section: Future Directions For Improving Corneal Transplantation Outcomesmentioning

confidence: 99%

Corneal Allografts: Factors for and against Acceptance

Sakowska

Glasner

Zieliński

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

Cornea is one of the most commonly transplanted tissues worldwide. However, it is usually omitted in the field of transplantology. Transplantation of the cornea is performed to treat many ocular diseases. It restores eyesight significantly improving the quality of life. Advancements in banking of explanted corneas and progressive surgical techniques increased availability and outcomes of transplantation. Despite the vast growth in the field of transplantation laboratory testing, standards for corneal transplantation still do not include HLA typing or alloantibody detection. This standard practice is based on immune privilege dogma that accounts for high success rates of corneal transplantation. However, the increasing need for retransplantation in high-risk patients with markedly higher risk of rejection causes ophthalmology transplantation centers to reevaluate their standard algorithms. In this review we discuss immune privilege mechanisms influencing the allograft acceptance and factors disrupting the natural immunosuppressive environment of the eye. Current developments in testing and immunosuppressive treatments (including cell therapies), when applied in corneal transplantation, may give very good results, decrease the possibility of rejection, and reduce the need for retransplantation, which is fairly frequent nowadays.

show abstract

Section: Future Directions For Improving Corneal Transplantation Outcomesmentioning

confidence: 99%